Saxony Capital Management LLC Purchases 2,505 Shares of Danaher Corporation $DHR

Saxony Capital Management LLC purchased a new position in Danaher Corporation (NYSE:DHR) during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm purchased 2,505 shares of the conglomerate’s stock, valued at approximately $555,000.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. Marquette Asset Management LLC raised its position in shares of Danaher by 192.1% during the third quarter. Marquette Asset Management LLC now owns 111 shares of the conglomerate’s stock valued at $25,000 after buying an additional 73 shares during the last quarter. N.E.W. Advisory Services LLC bought a new stake in shares of Danaher in the second quarter valued at about $25,000. Main Street Group LTD bought a new stake in shares of Danaher in the first quarter valued at about $25,000. Field & Main Bank acquired a new stake in Danaher during the second quarter worth about $29,000. Finally, Evolution Wealth Management Inc. grew its position in Danaher by 208.0% during the first quarter. Evolution Wealth Management Inc. now owns 154 shares of the conglomerate’s stock worth $29,000 after buying an additional 104 shares in the last quarter. Institutional investors own 79.05% of the company’s stock.

Danaher Price Performance

Shares of Danaher stock opened at $231.52 on Friday. The firm has a market cap of $162.76 billion, a P/E ratio of 41.12, a price-to-earnings-growth ratio of 2.82 and a beta of 0.76. The firm’s 50-day simple moving average is $213.55 and its 200-day simple moving average is $195.74. Danaher Corporation has a twelve month low of $160.93 and a twelve month high of $242.80. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.25 and a current ratio of 1.65.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Monday, July 20th. The conglomerate reported $1.94 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.85 by $0.09. Danaher had a net margin of 15.95% and a return on equity of 11.04%. The firm had revenue of $6.26 billion during the quarter, compared to analyst estimates of $6.12 billion. During the same quarter in the prior year, the business posted $0.77 earnings per share. The company’s quarterly revenue was up 5.5% compared to the same quarter last year. As a group, research analysts expect that Danaher Corporation will post 8.53 EPS for the current fiscal year.

Danaher Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be issued a dividend of $0.40 per share. This represents a $1.60 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date of this dividend is Wednesday, September 30th. Danaher’s payout ratio is presently 28.42%.

Danaher News Summary

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Danaher and NVIDIA announced an AI collaboration to combine Danaher’s scientific instruments, laboratory workflows, automation technology and software with NVIDIA’s accelerated computing and AI capabilities. The partnership is intended to advance autonomous science and speed drug discovery and other laboratory research. Danaher Collaborates with NVIDIA to Advance Autonomous Science
• Positive Sentiment: Danaher is also preparing to launch its first AI-powered autonomous laboratory, targeted to operate at commercial scale in early 2027. The initiative could support longer-term growth in laboratory automation and strengthen the company’s position in AI-enabled life-science research. How to Invest in AI Drug Discovery
• Positive Sentiment: Multiple Zacks reports say Danaher has a favorable combination of earnings-estimate trends and Earnings ESP, suggesting potential for the company to exceed consensus estimates in its next quarterly report. Danaher has also recently demonstrated earnings momentum, with its latest reported quarter exceeding both EPS and revenue expectations. Will Danaher Beat Estimates Again in Its Next Earnings Report?
• Neutral Sentiment: Danaher is projected to announce earnings on Wednesday. Investors will be watching revenue growth, management’s outlook and whether diagnostics and life-sciences demand support the anticipated improvement in earnings. Danaher Projected to Announce Earnings

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the company. Wells Fargo & Company lowered their price target on Danaher from $212.00 to $195.00 and set an “equal weight” rating on the stock in a research note on Wednesday, July 22nd. Morgan Stanley upped their price target on Danaher from $220.00 to $240.00 and gave the company an “overweight” rating in a report on Monday. Guggenheim raised their price objective on Danaher from $200.00 to $250.00 and gave the stock a “buy” rating in a research report on Thursday, October 1st. UBS Group assumed coverage on Danaher in a report on Wednesday, September 9th. They set a “buy” rating and a $250.00 price objective on the stock. Finally, Wall Street Zen raised Danaher from a “hold” rating to a “buy” rating in a report on Saturday, October 10th. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $235.41.

About Danaher

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.